Fig. 2: Pharmacological JNK inhibition and the effect on pancreatic cancer cell growth. | Cancer Gene Therapy

Fig. 2: Pharmacological JNK inhibition and the effect on pancreatic cancer cell growth.

From: c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1

Fig. 2

A, B Effect of the JNK inhibitor SP600125 on basal cell proliferation in WT cell lines (A) and after JNK KD (B). Indicated cells (10,000 cells/well) were cultured for 24 h in 96-well plates in complete medium followed by another 48 h in the absence or presence of increasing concentrations of SP600125 followed by the MTT assay. Results are shown as means (±SD) from three separate experiments with quadruplicate determinations compared to untreated control (DMSO only). B Cell proliferation was significantly inhibited at 10 µM SP600125 in wild-type (●) and Neo-17 (o). (C) Reduced JNK activity by SP600125 displayed by phosphorylated c-Jun. SP600125 markedly reduced JNK activity in MIA PaCa-2 and BxPC-3 cells while it was without effect in PANC-1. A representative blot is shown of three independent experiments. *p < 0.05 compared to JNK1 and JNK2 KD cells.

Back to article page